申请人:Makriyannis Alexandros
公开号:US20210300937A1
公开(公告)日:2021-09-30
Novel cannabinoid ligands represented by the general formulas I, II, and III and methods for preparation and use within which one or more of a fluorescent ligand, nitroxide spin label, metal chelate, biotin moiety, or group with enhanced polarity may be incorporated. The compounds can bind to and modulate the cannabinoid CB1 and CB2 receptors and thereby considered specific ligands for these receptors. Some of the disclosed compounds that bind to cannabinoid CB1 and CB2 receptors can exhibit tight or irreversible binding characteristics for these receptors. Due to the presence of the imaging/diagnostic and/or therapeutic functional groups including fluorescent groups, nitroxide spin labels, metal chelates, biotin moieties, and groups with enhanced polarity, the disclosed compounds may be useful as imaging/diagnostic tools and/or therapeutic agents.
新型大麻素配体由一般公式I、II和III表示,以及用于制备和使用的方法,其中可以包含一个或多个荧光配体、亚硝基自旋标记、金属螯合物、生物素基团或具有增强极性的基团。这些化合物可以结合并调节大麻素CB1和CB2受体,因此被认为是这些受体的特异性配体。一些公开的结合到大麻素CB1和CB2受体的化合物可能表现出对这些受体的紧密或不可逆结合特性。由于含有成像/诊断和/或治疗功能基团,包括荧光基团、亚硝基自旋标记、金属螯合物、生物素基团和具有增强极性的基团,公开的这些化合物可能作为成像/诊断工具和/或治疗剂而有用。